Fred Hutchinson Cancer Center

Marie Bleakley

Daniel Sommermeyer

Antoine Molaro

Guo-Liang Chew

Robson Dossa

Jay Francis Sarthy

The present disclosure describes methods of treating lymphoma that expresses a short histone H2A variant. In some embodiments, the method can comprise collecting a sample from a subject having or suspected of having lymphoma, detecting a short histone H2A variant (sH2A) expression level in the sample collected from the subject, and administering to the subject a therapeutically effective dose of an anthracycline agent, if the subject has sH2A variant expression level that is detectable. In other embodiments, the sH2A is the H2A.B variant. In other embodiments, the anthracycline agent can be aclarubicin.

Identification and treatment of T-cell epitopes of short H2A oncohistones

The present disclosure provides compositions and methods for targeting a minor histocompatibility (H) antigen (HA-1) to, for example, prevent or manage relapse of a hematological malignancy after allogeneic hematopoietic stem cell transplantation (HCT). Also provided are transgene constructs encoding engineered binding proteins, such as a T cell receptor or a chimeric antigen receptor, optionally encoding additional components such as a co-receptor and/or safety switch. Such transgene constructs can be transduced into an immune cell, such as a T cell, and used as an immunotherapy in a subject having a hematological malignancy or at risk for recurrence of the hematological malignancy (e.g., leukemia, lymphoma, myeloma).

Growing community of inventors

Seattle, WA, United States of America

Marie Bleakley